March 27, 2009 / 1:10 PM / 10 years ago

U.S. FDA staff question Stryker spine putty data

WASHINGTON, March 27 (Reuters) - U.S. reviewers questioned safety and effectiveness data supplied by Stryker Corp (SYK.N) on a bone-growth putty for spinal surgery in documents released on Friday.

“Based on reviews of these data, the agency has questions whether or not this combination product can be considered relatively safe and effective when compared to” a control treatment, Food and Drug Administration staff said in their analysis.

An FDA advisory panel will consider the product, OP-1 putty, at a public meeting on Tuesday. (Reporting by Lisa Richwine; editing by Gerald E. McCormick)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below